Download Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Chagas Disease Management Market: By Treatment Type, By Drug Type, By Distribution Channel, and Region Forecast 2019-2030
Chagas Disease Management Market: By Treatment Type, By Drug Type, By Distribution Channel, and Region Forecast 2019-2030
Chagas Disease Management Market was valued at US$ 5.72 million in 2023 and is expected to witness a CAGR of 7.6% from 2024-2030. Chagas disease or American trypanosomiasis is a tropical parasitic disease caused by Trypanosoma cruzi. Chagas disease is transmitted by kissing bugs or triatomine bugs. Chagas disease can also be transmitted through blood transfusions, from mother to fetus during pregnancy, and sometimes it causes through organ transplantation. The symptoms of the Chagas disease in the early stage include swollen lymph nodes, fever, headache, and local swelling at the site of the bite. The chronic symptoms will appear after 8-12 weeks that may include expansion of ventricles leads to the heart failure, oesophagus or colon may cause death. The diagnosis of Chagas disease is complicated, require laboratory analysis of blood samples for the detection of antibodies against the Trypanosome cruzi.
The Chagas disease is majorly present in the Latin America and spreading to North America and Europe region. Increase in the Chagas disease population in Latin America region and, rise in the prevalence of Chagas disease due to unhygienic conditions might fuel the growth of the market over the forecast period. In addition, an increase in the research and development of new products is one of the main factors that drive the growth of the market. However, lack of awareness regarding the Chagas disease treatment, a limited number of approved products in the current market, and supply chain issues with Chagas disease drugs will hamper the growth of the market over the forecast period.
Study Period
2025-2031Base Year
2024CAGR
7.6%Largest Market
Latin AmericaFastest Growing Market
North-America
Benznidazole is a vital antiparasitic medication used to treat Chagas disease. The Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT) approved benznidazole, a medication developed by Laboratorio Elea Phoenix SA, for paediatric use in the treatment of Chagas disease in April 2018. Argentina now has the highest number of people infected with the Chagas disease. According to data given by Mundo Sano (an Argentine non-governmental organisation), over 7,300,000 people in Argentina were exposed to Chagas disease in 2017, with about 1,600,000 becoming infected. As a result, new drug approvals are projected to drive market growth in the near future.
The approval of medications to treat Chagas disease is projected to drive the Chagas Disease Management Market's growth in the near future. The campaign aims to raise public awareness about Chagas disease, which is still widespread in Latin American countries and affects around 6 million people worldwide. The World Health Organization (WHO) initiated a programme in 2007 to raise Chagas disease treatment rates and eradicate the disease. Bayer HealthCare, which makes the drug nifurtimox, which is used to treat Chagas disease, contributed to this WHO initiative. From 2012 through 2017, Bayer is expected to distribute 5 million tablets free of charge, according to the deal. In the foreseeable future, such initiatives are projected to boost market expansion.
Chagas disease is dominant in Latin America region and nowadays it is developing in the rest of world owing to the population mobility from Latin America. According to World Health Organization (WHO), about 8 million people are suffering from Chagas disease in worldwide, and majority of the people living in Latin America region. In addition, about 10,000 people die every year with the Chagas disease. Less number of products available in the market for treatment, and poor diagnostic methods to detect in the Latin America region are the major challenges for the market in Latin America region. North America and Europe are the key regions for market owing to increase in the prevalence of Chagas disease according to CDC, approximately 300,000 people are suffering from the Chagas disease in the North America region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2023 |
US$ 5.72 million |
|
Market CAGR |
7.6% |
|
By Treatment Type |
|
|
By Drug Type |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The chagas disease management market size was valued at US$ 5.72 million in 2023 and is set to grow at a CAGR of 7.6% from 2024-2030.
AstraZeneca, Bayer AG, Daiichi Sankyo Company Ltd, Eisai Co Ltd, GlaxoSmithKline Plc., Grupo Praxis Pharmaceutical SA, KaloBios Pharmaceuticals, Kancera AB
| 1. Executive Summary |
| 2. Global Chagas Disease Management Market Introduction |
| 2.1.Global Chagas Disease Management Market - Taxonomy |
| 2.2.Global Chagas Disease Management Market - Definitions |
| 2.2.1.Treatment Type |
| 2.2.2.Drug Type |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3. Global Chagas Disease Management Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Chagas Disease Management Market Analysis, 2019 - 2030 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Chagas Disease Management Market By Treatment Type, 2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Antiparasitic treatment |
| 5.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Symptomatic treatment |
| 5.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Chagas Disease Management Market By Drug Type, 2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Benznidazole |
| 6.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Nifurtimox |
| 6.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Chagas Disease Management Market By Distribution Channel, 2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Online Pharmacies |
| 7.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Retail Pharmacies |
| 7.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Chagas Disease Management Market By Region, 2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Chagas Disease Management Market ,2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Treatment Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Antiparasitic treatment |
| 9.1.2.Symptomatic treatment |
| 9.2. Drug Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Benznidazole |
| 9.2.2.Nifurtimox |
| 9.3. Distribution Channel Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital Pharmacies |
| 9.3.2.Online Pharmacies |
| 9.3.3.Retail Pharmacies |
| 9.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Chagas Disease Management Market ,2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antiparasitic treatment |
| 10.1.2.Symptomatic treatment |
| 10.2. Drug Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Benznidazole |
| 10.2.2.Nifurtimox |
| 10.3. Distribution Channel Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital Pharmacies |
| 10.3.2.Online Pharmacies |
| 10.3.3.Retail Pharmacies |
| 10.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Chagas Disease Management Market ,2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antiparasitic treatment |
| 11.1.2.Symptomatic treatment |
| 11.2. Drug Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Benznidazole |
| 11.2.2.Nifurtimox |
| 11.3. Distribution Channel Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital Pharmacies |
| 11.3.2.Online Pharmacies |
| 11.3.3.Retail Pharmacies |
| 11.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Chagas Disease Management Market ,2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antiparasitic treatment |
| 12.1.2.Symptomatic treatment |
| 12.2. Drug Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Benznidazole |
| 12.2.2.Nifurtimox |
| 12.3. Distribution Channel Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital Pharmacies |
| 12.3.2.Online Pharmacies |
| 12.3.3.Retail Pharmacies |
| 12.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Chagas Disease Management Market ,2019 - 2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antiparasitic treatment |
| 13.1.2.Symptomatic treatment |
| 13.2. Drug Type Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Benznidazole |
| 13.2.2.Nifurtimox |
| 13.3. Distribution Channel Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital Pharmacies |
| 13.3.2.Online Pharmacies |
| 13.3.3.Retail Pharmacies |
| 13.4. Country Analysis 2019 - 2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.AstraZeneca (U.K) |
| 14.2.2.Bayer AG (Germany) |
| 14.2.3.Daiichi Sankyo Company Ltd (Japan) |
| 14.2.4.Eisai Co Ltd (Japan) |
| 14.2.5.GlaxoSmithKline Plc. (U.K) |
| 14.2.6.Grupo Praxis Pharmaceutical SA (Spain) |
| 14.2.7.KaloBios Pharmaceuticals, Inc. (U.S.) |
| 14.2.8.Kancera AB (Sweden) |
| 14.2.9.Novartis AG (Switzerland) |
| 14.2.10.Laboratorio Elea S.A.C.I.F. y A (Argentina) |
| 14.2.11.Oblita Therapeutics BVBA (Belgium) |
| 14.2.12.Sanofi (France) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.